Involvement/NN
of/IN
phospholipase/NN
D/NN
in/IN
the/DT
activation/NN
of/IN
transcription/NN
factor/NN
AP-1/NN
in/IN
human/JJ
T/NN
lymphoid/JJ
Jurkat/NN
cells/NNS
./.

The/DT
induction/NN
of/IN
the/DT
AP-1/NN
transcription/NN
factor/NN
has/VBZ
been/VBN
ascribed/VBN
to/TO
the/DT
early/JJ
events/NNS
leading/VBG
to/TO
T/NN
lymphocyte/NN
activation/NN
./.
=====
We/PRP
have/VBP
examined/VBN
the/DT
possibility/NN
that/IN
stimulation/NN
of/IN
phospholipase/NN
D/NN
(/(
PLD/NN
)/)
may/MD
regulate/VB
activation/NN
of/IN
transcription/NN
factor/NN
AP-1/NN
in/IN
human/JJ
T/NN
cells/NNS
by/IN
transfecting/VBG
human/JJ
T/NN
lymphocyte/NN
Jurkat/NN
cells/NNS
with/IN
a/DT
plasmid/NN
containing/VBG
an/DT
AP-1/NN
enhancer/NN
element/NN
and/CC
a/DT
chloramphenicol/NN
acetyltransferase/NN
reporter/NN
gene/NN
./.
=====
We/PRP
have/VBP
detected/VBN
activatable/JJ
PLD/NN
in/IN
Jurkat/NN
cells/NNS
,/,
and/CC
we/PRP
have/VBP
found/VBN
that/IN
addition/NN
of/IN
phosphatidic/JJ
acid/NN
(/(
PA/NN
)/)
,/,
the/DT
physiologic/JJ
product/NN
of/IN
PLD/NN
action/NN
on/IN
phospholipids/NNS
,/,
is/VBZ
rapidly/RB
incorporated/VBN
into/IN
Jurkat/NN
cells/NNS
and/CC
leads/VBZ
to/TO
activation/NN
of/IN
transcription/NN
factor/NN
AP-1/NN
./.
=====
Treatment/NN
of/IN
Jurkat/NN
cells/NNS
with/IN
anti-CD3/JJ
mAb/NN
activated/VBD
both/CC
PLD/NN
and/CC
transcription/NN
factor/NN
AP-1/NN
./.
=====
Wortmannin/NN
,/,
an/DT
inhibitor/NN
of/IN
receptor-coupled/JJ
PLD/NN
activation/NN
,/,
blocked/VBD
the/DT
anti-CD3-induced/JJ
increases/NNS
in/IN
both/CC
PLD/NN
activity/NN
and/CC
AP-1/NN
enhancer/NN
activity/NN
./.
=====
We/PRP
found/VBD
a/DT
good/JJ
correlation/NN
in/IN
the/DT
transfected/VBN
cells/NNS
between/IN
PLD/NN
activation/NN
and/CC
induction/NN
of/IN
AP-1/NN
enhancer/NN
activity/NN
under/IN
different/JJ
experimental/JJ
conditions/NNS
./.
=====
Furthermore/RB
,/,
ethanol/NN
,/,
an/DT
inhibitor/NN
of/IN
the/DT
PLD/NN
pathway/NN
,/,
blocked/VBD
the/DT
anti-CD3-stimulated/JJ
AP-1/NN
enhancer/NN
activity/NN
./.
=====
However/RB
,/,
this/DT
anti-CD3-mediated/JJ
response/NN
was/VBD
not/RB
inhibited/VBN
by/IN
neomycin/NN
,/,
an/DT
inhibitor/NN
of/IN
phosphoinositide/JJ
hydrolysis/NN
./.
=====
The/DT
increases/NNS
in/IN
AP-1/NN
enhancer/NN
activity/NN
induced/VBN
by/IN
PA/NN
or/CC
anti-CD3/JJ
mAb/NN
were/VBD
efficiently/RB
abrogated/VBN
by/IN
the/DT
presence/NN
of/IN
propranolol/NN
,/,
an/DT
inhibitor/NN
of/IN
PA/NN
phosphohydrolase/NN
and/CC
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
./.
=====
Furthermore/RB
,/,
the/DT
PA-/NN
and/CC
the/DT
anti-CD3-induced/JJ
increases/NNS
in/IN
AP-1/NN
enhancer/NN
activity/NN
were/VBD
blocked/VBN
by/IN
the/DT
presence/NN
of/IN
PKC/NN
inhibitors/NNS
or/CC
by/IN
PKC/NN
down-regulation/NN
./.
=====
These/DT
data/NNS
indicate/VBP
that/IN
PLD/NN
stimulation/NN
can/MD
activate/VB
the/DT
transcription/NN
factor/NN
AP-1/NN
in/IN
T/NN
lymphocytes/NNS
,/,
and/CC
suggest/VBP
that/IN
the/DT
induction/NN
of/IN
AP-1/NN
enhancer/NN
factor/NN
activity/NN
by/IN
PA/NN
is/VBZ
mediated/VBN
via/IN
PKC/NN
stimulation/NN
,/,
either/CC
through/IN
a/DT
direct/JJ
activating/NN
effect/NN
of/IN
PA/NN
or/CC
through/IN
PA-derived/JJ
diacylglycerol/NN
formation/NN
./.
=====
These/DT
data/NNS
also/RB
provide/VBP
evidence/NN
for/IN
a/DT
role/NN
of/IN
PLD-derived/JJ
lipids/NNS
in/IN
the/DT
induction/NN
of/IN
AP-1/NN
enhancer/NN
activity/NN
resulting/VBG
from/IN
stimulation/NN
of/IN
the/DT
TCR/CD3/NN
complex/NN
,/,
suggesting/VBG
that/IN
increased/VBN
PLD/NN
activity/NN
can/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
T/NN
lymphocyte/NN
activation/NN
./.